Häge, Alexander http://orcid.org/0000-0002-3434-2995
Alm, Barbara
Banaschewski, Tobias
Becker, Katja
Colla, Michael
Freitag, Christine
Geissler, Julia
von Gontard, Alexander
Graf, Erika
Haack-Dees, Barbara
Hänig, Susann
Hennighausen, Klaus
Hohmann, Sarah
Jacob, Christian
Jaite, Charlotte
Jennen-Steinmetz, Christine
Kappel, Viola
Matthies, Swantje
Philipsen, Alexandra
Poustka, Luise
Retz, Wolfgang
Rösler, Michael
Schneider-Momm, Katja
Sobanski, Esther
Vloet, Timo D.
Warnke, Andreas
Jans, Thomas
Funding for this research was provided by:
BMBF (01GV0605, 01GV0606)
Article History
Received: 27 April 2017
Accepted: 13 January 2018
First Online: 23 January 2018
Compliance with ethical standards
:
: A. Häge received speakers’ fees, was on advisory boards, or has been involved in clinical trials by Shire, Janssen-Cilag, Otsuka, Lundbeck, and Servier. B. Alm was involved in Phase-III studies for Medice, Eli Lilly, and Novartis; was on Eli Lilly’s advisory board; and received speakers’ honoraria from Medice. T. Banaschewski served in an advisory or consultancy role for Actelion, Hexal Pharma, Lilly, Medice, Novartis, and Shire. He received conference support or speaker’s fee by Medice, Novartis, and Shire. He is/has been involved in clinical trials conducted by Shire & Viforpharma. He received royalities from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press. The present work is unrelated to the above grants and relationships. K. Becker was on the Advisory Board of Eli Lilly/Germany, was member of the Scientific Committee of Shire, and received speakers’ honorary (independent lecture content) by Shire. No research/clinical trials sponsored by pharmaceutical industry within the last 5 years. M. Colla was on advisory boards, received speakers’ honoraria, and participated in Phase-III studies for Shire, Eli Lilly, and Novartis within the last 3 years. C. Freitag received speakers’ honoraria (independent lecture content) from Eli Lilly, Novartis, and Shire during the last 3 years and was an independent clinical consultant for Desitin in 2010. A. von Gontard was invited by Eli Lilly to the present two lectures. S. Hohmann received speakers’ honoraria from Jansen Cilag in 2012. C. Jacob received speakers’ honoraria from Novartis and Medice and is a member of the adult ADHD Advisory Board of the latter company. S. Matthies received speakers’ fees from Janssen-Cilag and was involved in clinical trials conducted by Janssen-Cilag and Lilly as a study physician in the years 2007–2009. A. Philipsen was on advisory boards, presented lectures, was involved in Phase-III studies, and received travel grants from Eli Lilly, Janssen-Cilag, Medice, Novartis, and Shire within the last 3 years; she is the author of books and articles on psychotherapy published by Elsevier, Hogrefe, Schattauer, Kohlhammer, and Karger; she is involved in clinical trials funded by the German Federal Ministry of Education and Research. L. Poustka received speakers’ honoraria from Eli Lilly and Shire during the last 3 years. W. Retz received speakers’ honoraria from and is on Medice, Novartis, and Shire advisory boards; he is involved in clinical trials for the German Ministry of Education and Research (BMBF), Novartis, Medice, and Vifor. M. Rösler is a member of the Medice, Janssen, and Shire speakers’ bureaus, is a member of Lilly, Shire, Medice, and Janssen advisory boards, and performed clinical trials for Medice and Lilly. E. Sobanski was on advisory boards, was involved in Phase-III studies or investigator-initiated trials, and presented lectures for Medice, Shire, Eli Lilly, and Novartis within the last 3 years. A. Warnke received speakers’ fees from Janssen-Cilag, Medice, Novartis, and Lilly and was involved in clinical trials conducted by Lilly, Novartis, Medice, and Shire; no fees or research funding have been awarded in the last 2 years. All other authors declared no conflicting interests (E. Graf, J. Geissler, B. Haack-Dees, S. Hänig, K. Hennighausen, C. Jaite, T. Jans, T. D. Vloet, C. Jennen-Steinmetz, V. Kappel, and K. Schneider-Momm).
: The study received appropriate ethics committee approval from the leading Ethics Committee (Faculty of Medicine, Würzburg University, 120/06) and the local ethics committees and was authorized by the competent German authorities. The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All participants gave their informed consent and assent prior to their inclusion in the study. The study is registered in Current Controlled Trials (ISRCTN73911400).